Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TMEM244 was initially annotated as 'transmembrane protein 244' and presumed to be a membrane protein based on in silico predictions; however, recent experimental evidence shows that TMEM244 is not translated into a protein and instead functions as a long non-coding RNA (lncRNA). The TMEM244 transcript is primarily localized to the cytoplasm and is essential for the proliferation and survival of cutaneous T-cell lymphoma (CTCL) cells. Expression of TMEM244 is a potential diagnostic marker, particularly distinguishing Sézary syndrome from similar conditions. There is no experimental confirmation of TMEM244 protein expression, and its gene does not display protein-coding potential. While annotated as a transmembrane protein in some databases, consensus from recent literature is that TMEM244 is a cytoplasmic lncRNA with roles in malignant T-cell biology, not a classical receptor, enzyme, or transmembrane protein[1][2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long non-coding RNA TMEM244 (TMEM244).